Hermetica Superfood Encyclopedia
The Short Answer
Brachyglottis repanda contains the labdane diterpenoid 13(E)-labd-13-ene-8α,15-diol, which demonstrates antiviral activity against human rhinoviruses (IC₅₀ 0.87–2.68 μg/ml) and potent antimicrobial action (MIC 0.092 μg/ml against gram-negative bacteria), alongside alkaloids and lactone-type compounds that exhibit in vitro cytotoxicity. The most quantified preclinical finding is antifungal activity against Trichophyton mentagrophytes combined with partial polio virus inhibition (25% at 150 μg/disk), though no human clinical trial has yet validated these effects for wound healing or dermatological application.
CategoryHerb
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordBrachyglottis repanda benefits
Rangiora — botanical close-up
Health Benefits
**Wound and Ulcer Healing (Topical)**
Leaves have been applied as poultices in Māori rongoā for centuries to treat old sores, boils, and chronic ulcers; antimicrobial constituents including the MIC-active labdane diterpenoid may reduce microbial burden at wound sites, though no controlled trials confirm efficacy.
**Antiviral Activity**
The isolated compound 13(E)-labd-13-ene-8α,15-diol showed selective antiviral potency against human rhinovirus serotypes HRV-2 and HRV-3 (IC₅₀ 0.87–2.68 μg/ml) with a selectivity index supported by a CC₅₀ of 59.45 μg/ml, suggesting a therapeutic window in vitro.
**Antifungal Properties**
Ethanol extracts demonstrated potent activity against Trichophyton mentagrophytes, a dermatophyte responsible for tinea infections, which is consistent with the plant's traditional use for skin diseases; the active fraction and concentration thresholds require further characterisation.
**Antibacterial Action**: A MIC of 0
092 μg/ml against gram-negative bacteria was recorded for the labdane diterpenoid isolate, indicating high intrinsic potency that may translate to surface decontamination in topical formulations if bioavailability and stability can be established.
**In Vitro Antiproliferative Effects**
Polar fraction 64-3 suppressed viability of A549 lung carcinoma and Hep2 laryngeal carcinoma cells below 50% at 32 μg/ml, and showed a P388 murine leukemia IC₅₀ of 10,051 ng/ml, indicating concentration-dependent cytostatic or cytotoxic activity attributable to alkaloid and lactone constituents detected by ¹H-NMR.
**Oral Hygiene and Aromatic Use**
The aromatic gum exuded from bark incisions was historically chewed as a masticatory to address bad breath and was processed into scented pomades; while no antimicrobial oral studies exist, the antimicrobial profile of plant extracts provides a plausible mechanistic basis.
**Anti-inflammatory Potential (Inferred)**
Traditional use for inflammatory skin conditions such as boils and abscesses implies an anti-inflammatory component, and the presence of terpenoid and alkaloid classes is broadly associated with prostaglandin and cytokine pathway modulation in related Brachyglottis species, though direct evidence for this species is absent.
Origin & History
Natural habitat
Brachyglottis repanda is a fast-growing native shrub or small tree endemic to New Zealand (Aotearoa), found throughout the North Island and northern South Island in coastal scrubland, forest margins, and disturbed habitats from sea level to approximately 1,000 metres elevation. It thrives in well-drained soils with high light exposure and is notably tolerant of coastal wind and salt spray, making it a common pioneer species in regenerating bush. The plant was not traditionally cultivated but was harvested from wild stands, with large, soft leaves up to 30 cm across making it easily identifiable and accessible to Māori communities throughout its native range.
“Brachyglottis repanda holds a well-established place in Māori rongoā (traditional healing), where it has been used for multiple generations as a topical remedy for skin ailments including old sores, boils, ulcers, and infected wounds, with healers preparing leaf poultices that were applied directly to affected areas. The plant's Māori name 'rangiora' is widely recognised across iwi (tribes) of the North Island, and it features in oral traditions as one of several accessible bush medicines sourced from forest margins and scrubland near settlements. Beyond medicinal use, the broad, soft leaves had practical cultural significance as wrapping materials for prepared foods such as steamed fernroot cakes and eels, reflecting the Māori practice of integrating plant knowledge across culinary and medicinal domains. The aromatic gum from the bark was also valued as a cosmetic and masticatory, demonstrating that the plant was understood to have multiple functional properties, a holistic use pattern consistent with broader Polynesian ethnobotanical traditions that recognised plants as serving community health, food, and aesthetic needs simultaneously.”Traditional Medicine
Scientific Research
The current evidence base for Brachyglottis repanda consists exclusively of in vitro laboratory studies, with no peer-reviewed human clinical trials, animal efficacy studies, or randomised controlled trials published to date; this places the ingredient firmly in the preclinical research tier. Key published findings include bioassay-guided fractionation of ethanol leaf extracts identifying antiviral, antibacterial, antifungal, and cytotoxic activities across multiple fractions, with the most potent result being HRV-2/3 inhibition (IC₅₀ 0.87–2.68 μg/ml) by the purified labdane diterpenoid and a MIC of 0.092 μg/ml for antibacterial activity. Cytotoxicity data derive from standard NCI-protocol P388 mouse leukemia assays and human cancer cell line viability assays (A549, Hep2), which are screening tools rather than proof of therapeutic efficacy and carry no direct clinical translation. An ongoing research programme (anticipated 2024–2026) aims to conduct plaque reduction assays to refine antiviral IC₅₀ and CC₅₀ parameters, but results are not yet available, and the overall evidence volume remains very low with significant gaps in bioavailability, pharmacokinetics, and in vivo validation.
Preparation & Dosage
Traditional preparation
**Traditional Leaf Poultice**
Fresh or bruised leaves of Brachyglottis repanda are mashed and mixed with a carrier oil (historically olive oil or animal fat) and applied directly to wounds, boils, or ulcerous skin lesions; no standardised frequency or quantity has been established.
**Leaf Wrap (Non-medicinal/Food)**
Large leaves are used to wrap foods such as hīnau cakes, aruhe (fernroot) meal, and eels before steaming or earth-oven cooking, functioning as a food-grade wrapping material rather than a medicinal delivery form.
**Aromatic Gum/Pomade**
Bark is incised to collect exuded gum, which is then heated gently in oil to produce a scented preparation used as a masticatory for oral hygiene or as a hair and skin pomade; no therapeutic dose has been quantified.
**Ethanol Extract (Research Grade Only)**
Laboratory studies used crude ethanol extracts at concentrations of 150 μg/disk for antiviral disk assays and fractions at 32–62,500 ng/ml for cytotoxicity assays; these are not supplemental doses and should not be replicated outside controlled laboratory settings.
**No Standardised Supplement Form**
No capsule, tablet, tincture, or standardised extract of Brachyglottis repanda is commercially available or clinically validated; internal human supplementation is not recommended given current toxicity data and absence of dosage research.
Nutritional Profile
Brachyglottis repanda has not been subject to formal nutritional analysis, and no macronutrient, micronutrient, or caloric data are documented in the scientific literature for any plant part. Phytochemically, the most characterised constituent is the labdane diterpenoid 13(E)-labd-13-ene-8α,15-diol isolated from ethanol leaf extracts, with bioactivity quantified but absolute tissue concentration not reported. ¹H-NMR analysis of polar fractions indicates the presence of alkaloids and sesquiterpene-type lactone compounds (chemical shifts 1.60–2.50 ppm for methylene/methyl groups and 4.50–6.30 ppm for olefinic/lactone protons), though neither structural identity nor tissue concentration has been fully established. No vitamins, essential fatty acids, minerals, or dietary fibre content have been measured, and the plant is not considered a food source; its leaves are noted to be potentially toxic to livestock, suggesting the presence of secondary metabolites that could be harmful if consumed in quantity, further undermining any nutritional application.
How It Works
Mechanism of Action
The principal characterised compound, 13(E)-labd-13-ene-8α,15-diol, is a bicyclic labdane diterpenoid whose antiviral mechanism against human rhinoviruses likely involves interference with viral capsid protein binding or host cell attachment, a mode of action common to terpenoids of this structural class, though the precise receptor target in this species has not been experimentally confirmed. Alkaloids and lactone-type compounds detected by ¹H-NMR in the polar fraction (chemical shifts 1.60–2.50 and 4.50–6.30 ppm) are structurally consistent with sesquiterpene lactones, a class known to alkylate nuclear factor-kappa B (NF-κB) pathway components via Michael addition to cysteine residues, potentially suppressing inflammatory cytokine transcription. The antiproliferative effects on A549, Hep2, and P388 cell lines at low-to-mid microgram concentrations suggest induction of intrinsic apoptotic pathways or disruption of cell cycle progression, though specific caspase activation, Bcl-2 family modulation, or checkpoint kinase inhibition have not been mechanistically mapped in this plant's extracts. Antifungal activity against Trichophyton mentagrophytes may involve membrane ergosterol disruption, a common mechanism for terpenoid antifungals, while the sub-0.1 μg/ml MIC against gram-negative bacteria implies either outer membrane permeabilisation or inhibition of a conserved metabolic enzyme, neither of which has been confirmed through target identification studies.
Clinical Evidence
No human clinical trials have been conducted on Brachyglottis repanda extracts, isolated compounds, or any standardised preparation derived from this plant for any indication, including skin disease, wound healing, antiviral, or anticancer applications. All quantified outcome data originate from cell-free or cell-based in vitro assays: the strongest signals are antiviral (HRV IC₅₀ 0.87–2.68 μg/ml), antibacterial (MIC 0.092 μg/ml), and selective cytotoxicity at 32 μg/ml against two cancer cell lines, none of which have been replicated in animal models. Confidence in clinical benefit is therefore very low, and extrapolation from these in vitro findings to human therapeutic outcomes is not scientifically justified at this stage. Traditional Māori ethnobotanical records provide centuries of topical use for wound management, which represents the primary real-world 'evidence' and is the basis for ongoing scientific interest, but does not constitute clinical proof of efficacy or safety.
Safety & Interactions
Brachyglottis repanda presents meaningful safety concerns that preclude recommendation for internal human use: the growing leaf tips are documented to be poisonous to livestock, and the plant's gum and honey derived from its flowers are noted as potentially toxic and may require purification before any use, suggesting the presence of systemically harmful secondary metabolites at concentrations relevant to ingestion. In vitro cytotoxicity was observed on BSC (normal) cells and on A549 and Hep2 cancer lines at low-to-mid microgram concentrations, which raises theoretical concerns about genotoxicity or organotoxicity in vivo, though no acute or chronic toxicity studies in animals or humans have been conducted to establish a no-observed-adverse-effect level (NOAEL) or maximum tolerable dose. No drug interactions have been formally studied, but given the presence of alkaloids and terpenoids with enzyme-modulating potential, interactions with cytochrome P450 substrates, anticoagulants, or immunosuppressants cannot be excluded. Topical use following traditional preparation may carry lower systemic risk than internal use, but contact dermatitis potential has not been assessed, and use during pregnancy or lactation should be avoided entirely given the absence of safety data and the known livestock toxicity of plant constituents.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Brachyglottis repandaRangioraRongoaPukapukaBushman's friend
Frequently Asked Questions
What is rangiora (Brachyglottis repanda) used for in Māori medicine?
In Māori rongoā (traditional healing), rangiora leaves are primarily used as a topical treatment for skin conditions including old sores, boils, ulcers, and infected wounds, with leaves mashed and mixed with oil to form a poultice applied directly to affected skin. The aromatic gum from bark incisions has also been used as a masticatory for bad breath and as a scented pomade. These uses reflect centuries of traditional knowledge, though no controlled clinical trials have validated the efficacy of any preparation.
Does Brachyglottis repanda have antiviral properties?
In vitro laboratory studies have identified a labdane diterpenoid compound, 13(E)-labd-13-ene-8α,15-diol, isolated from ethanol extracts of Brachyglottis repanda that inhibits human rhinovirus serotypes HRV-2 and HRV-3 with an IC₅₀ of 0.87–2.68 μg/ml and a cytotoxicity threshold (CC₅₀) of 59.45 μg/ml, suggesting a meaningful in vitro selectivity window. Crude extracts also showed 25% inhibition of poliovirus at 150 μg/disk. However, these are cell-based findings only, and no human or animal antiviral trials have been conducted.
Is rangiora safe to eat or take internally?
Internal use of Brachyglottis repanda is not considered safe based on available evidence: the growing leaf tips are documented to be poisonous to livestock, and the plant's gum and flower-derived honey are noted as potentially toxic, possibly requiring purification before any use. In vitro cytotoxicity has been observed on normal BSC cells as well as cancer cell lines at low microgram concentrations. No human toxicity studies have been conducted, and internal supplementation is not recommended without substantially more safety data.
What active compounds are found in Brachyglottis repanda?
The best-characterised bioactive compound is the labdane diterpenoid 13(E)-labd-13-ene-8α,15-diol, isolated from ethanol leaf extracts and shown to have antiviral and antibacterial activity (MIC 0.092 μg/ml against gram-negative bacteria). ¹H-NMR analysis of polar fractions also indicates the presence of alkaloids and sesquiterpene lactone-type compounds detectable at chemical shifts of 1.60–2.50 ppm and 4.50–6.30 ppm. Absolute tissue concentrations of these compounds have not been quantified, and the full phytochemical profile remains incompletely characterised.
Are there clinical trials on rangiora for skin disease?
No human clinical trials have been conducted on Brachyglottis repanda for skin disease, wound healing, or any other medical indication. All published scientific data come from in vitro (cell-based) assays demonstrating antifungal activity against Trichophyton mentagrophytes, antibacterial effects, antiviral activity against rhinoviruses, and cytotoxicity on cancer cell lines. Ongoing research (2024–2026) is planned to refine antiviral potency measurements using plaque assays, but results are not yet published, and the overall evidence base remains preliminary.
Is rangiora (Brachyglottis repanda) safe to use topically on open wounds or broken skin?
Rangiora leaves have a long history of topical application in Māori rongoā for wounds and ulcers, with labdane diterpenoids showing antimicrobial activity that may help reduce infection risk. However, no controlled clinical trials have confirmed safety or efficacy for open wounds, so patch testing on a small area is advisable before widespread application. If infection signs develop or wounds worsen, discontinue use and seek medical attention.
Can rangiora (Brachyglottis repanda) interact with topical antibiotics or antiseptics?
While rangiora contains antimicrobial compounds, there is no published research documenting interactions between Brachyglottis repanda and conventional topical antibiotics or antiseptics. Combining rangiora poultices with prescription wound treatments should be discussed with a healthcare provider to avoid interfering with clinical protocols or creating overlapping antimicrobial effects.
What is the difference between using fresh versus dried rangiora leaves for wound healing?
Traditional Māori application typically used fresh-harvested rangiora leaves as poultices, which may retain volatile compounds and moisture that support wound contact; dried forms are more shelf-stable but may have reduced potency of volatile constituents. No comparative studies directly measure efficacy differences between fresh and dried preparations, so preparation method should reflect traditional practice or personal tolerance.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w rongoa-brachyglottis-repanda curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
